Acro Biomedical Co., Ltd. (OTC: ACBM)

Acro Biomedical Co., Ltd. specializes in the development and marketing of nutritional products aimed at promoting wellness and a healthy lifestyle. Operating within the dietary supplement industry, the company focuses primarily on cordyceps-related products, a fungus traditionally used in Chinese medicine. Acro Biomedical sources its inventory from suppliers in Taiwan, with a single supplier accounting for all purchases in 2022. The company has not generated revenue since the second quarter of 2022 and currently holds no inventory or accounts receivable. Its business plan remains in preliminary stages, requiring significant funding for execution, with no guarantee of success.

The company generates revenue by purchasing cordyceps-based products from suppliers and selling them in bulk to customers. These customers either resell the products in their original form or use them as ingredients in their own formulations. Historically, sales have been limited to cordyceps-related products, though the company has previously marketed metallothionein MT-3 elixir and may explore other complementary products in the future. All sales activities were conducted by the former chief executive officer on a part-time basis, with no revenue reported since December 31, 2022.

Acro Biomedical operates in a competitive segment of the dietary supplement industry, where numerous companies market cordyceps products in both the United States and Asia. Key competitors include Real Mushrooms, Bulk Supplements, Terrasoul SuperFoods, NOW Foods, Aloha Medicinals, and Swanson Premium, many of which are better capitalized and more established. The company faces challenges in differentiating its offerings, particularly as it lacks intellectual property protections or proprietary formulations. Additionally, the high cost of cordyceps limits its potential use in applications such as chicken feed, where cheaper alternatives dominate the market. The company’s ability to compete hinges on securing funding, resuming operations, and successfully executing its business plan.

The company’s customer base consists of distributors and manufacturers that purchase cordyceps products in bulk for resale or incorporation into their own products. Historically, these customers have been located in Taiwan and Hong Kong, where they are responsible for complying with local regulations governing dietary supplements. Acro Biomedical has not sold products directly to consumers and currently has no active sales pipeline. Its reliance on a limited number of customers and suppliers exposes it to operational and financial risks.